Monoclonal Antibodies for Treatment of COVID-19: An Updated Review of Current Evidence

Saurabh Nimesh (1) , Pratibha Kumari (2) , Rohit Kumar (3) , Gosiya Gosiya (4) , Md. Quamuddin (5) , Md. Iftekhar Ahmad (6)
(1) Metro College of Health Sciences and Research , India
(2) Galgotias University , India
(3) Yogendra Nath Saxena College of Pharmacy and Research Centre , India
(4) Yogendra Nath Saxena College of Pharmacy and Research Centre , India
(5) Metro College of Health Sciences and Research , India
(6) Shri Gopichand College of Pharmacy , India

Abstract

The emergence of COVID-19 in December 2019 spurred a global effort to develop effective medical interventions. Therapeutic monoclonal antibodies (mAbs) have emerged as a promising strategy to combat the SARS-CoV-2 virus. Several mAbs targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein have received Emergency Use Authorization (EUA) for treating mild to moderate COVID-19. Additionally, human mAbs and hyperimmune plasma derived from recovered COVID-19 patients have been explored as potential therapeutic options. This review delves into the potential of mAbs for the diagnosis and treatment of COVID-19 infection. We discuss the mechanisms of action of mAbs, as well as their advantages and limitations. Furthermore, we explore the ongoing research and development efforts to optimize mAb-based therapies for COVID-19.

Full text article

Generated from XML file

References

Read More

Authors

Saurabh Nimesh
nimeshmiet@gmail.com (Primary Contact)
Rohit Kumar
Gosiya Gosiya
Md. Quamuddin
Author Biographies

Saurabh Nimesh, Metro College of Health Sciences and Research

Department of Pharmacology, Metro College of Health Sciences and Research, Greater Noida, Uttar Pradesh, India

Pratibha Kumari, Galgotias University

Department of Pharmacy, Galgotias University, Greater Noida, Uttar Pradesh, India

Rohit Kumar, Yogendra Nath Saxena College of Pharmacy and Research Centre

Department of Pharmacology, Yogendra Nath Saxena College of Pharmacy and Research Centre, Amroha, Uttar Pradesh, India

Gosiya Gosiya, Yogendra Nath Saxena College of Pharmacy and Research Centre

Department of Pharmacology, Yogendra Nath Saxena College of Pharmacy and Research Centre, Amroha, Uttar Pradesh, India

Md. Quamuddin, Metro College of Health Sciences and Research

Department of Pharmacology, Metro College of Health Sciences and Research, Greater Noida, Uttar Pradesh, India

Md. Iftekhar Ahmad, Shri Gopichand College of Pharmacy

Department of Pharmaceutics, Shri Gopichand College of Pharmacy, Baghpat, Uttar Pradesh, India

1.
Nimesh S, Kumari P, Kumar R, Gosiya G, Quamuddin M, Ahmad MI. Monoclonal Antibodies for Treatment of COVID-19: An Updated Review of Current Evidence. Borneo J Pharm [Internet]. 2024Nov.30 [cited 2025Feb.3];7(4):342-56. Available from: https://journal.umpr.ac.id/index.php/bjop/article/view/6365

Article Details